


PHARMACEUTICAL 2021

NEXIEN BIOPHARMA INC. Rank 409 of 409







PHARMACEUTICAL 2021

NEXIEN BIOPHARMA INC. Rank 409 of 409

The relative strengths and weaknesses of NEXIEN BIOPHARMA INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NEXIEN BIOPHARMA INC. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 9,467% points. The greatest weakness of NEXIEN BIOPHARMA INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 40,978% points.

The company's Economic Capital Ratio, given in the ranking table, is -41,796%, being 41,441% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	23
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	29
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	176
Other Liabilities	0
Other Net Income	-0.033
Property and Equipment	0
Research and Development	0
Revenues	0
Selling, General and Administrative Expense	2,495

Output Variable	Value in 1000 USD
Assets	23
Liabilities	29
Expenses	2,672
Stockholders Equity	-6.4
Net Income	-2,672
Comprehensive Net Income	-2,672
Economic Capital Ratio	-41,796%

